Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Acute Respiratory Distress-Syndrome | Research

Evaluation of the safety and efficacy of extracorporeal carbon dioxide removal in the critically ill using the PrismaLung+ device

Authors: Ravindranath Tiruvoipati, Jarryd Ludski, Sachin Gupta, Ashwin Subramaniam, Mallikarjuna Ponnapa Reddy, Eldho Paul, Kavi Haji

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Several extracorporeal carbon dioxide removal (ECCO2R) devices are currently in use with variable efficacy and safety profiles. PrismaLung+ is an ECCO2R device that was recently introduced into clinical practice. It is a minimally invasive, low flow device that provides partial respiratory support with or without renal replacement therapy. Our aim was to describe the clinical characteristics, efficacy, and safety of PrismaLung+ in patients with acute hypercapnic respiratory failure.

Methods

All adult patients who required ECCO2R with PrismaLung+ for hypercapnic respiratory failure in our intensive care unit (ICU) during a 6-month period between March and September 2022 were included.

Results

Ten patients were included. The median age was 55.5 (IQR 41–68) years, with 8 (80%) male patients. Six patients had acute respiratory distress syndrome (ARDS), and two patients each had exacerbations of asthma and chronic obstructive pulmonary disease (COPD). All patients were receiving invasive mechanical ventilation at the time of initiation of ECCO2R. The median duration of ECCO2R was 71 h (IQR 57–219). A significant improvement in pH and PaCO2 was noted within 30 min of initiation of ECCO2R. Nine patients (90%) survived to weaning of ECCO2R, eight (80%) survived to ICU discharge and seven (70%) survived to hospital discharge. The median duration of ICU and hospital stays were 14.5 (IQR 8–30) and 17 (IQR 11–38) days, respectively. There were no patient-related complications with the use of ECCO2R. A total of 18 circuits were used in ten patients (median 2 per patient; IQR 1–2). Circuit thrombosis was noted in five circuits (28%) prior to reaching the expected circuit life with no adverse clinical consequences.

Conclusion(s)

PrismaLung+ rapidly improved PaCO2 and pH with a good clinical safety profile. Circuit thrombosis was the only complication. This data provides insight into the safety and efficacy of PrismaLung+ that could be useful for centres aspiring to introduce ECCO2R into their clinical practice.
Literature
1.
Hickling KG, Walsh J, Henderson S, Jackson R. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med. 1994;22:1568–78.CrossRefPubMed
2.
Amato MBP, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372:747–55.CrossRefPubMed
3.
Acute Respiratory Distress Syndrome Network; Roy G Brower MAM, Alan Morris, David Schoenfeld, B Taylor Thompson, Arthur Wheeler. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301–8.
4.
Barnes T, Zochios V, Parhar K. Re-examining Permissive Hypercapnia in ARDS: A Narrative Review. Chest. 2018;154:185–95.CrossRef
5.
Nin N, Muriel A, Peñuelas O, et al. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. Intensive Care Med. 2017;43:200–8.CrossRefPubMedPubMedCentral
6.
Tiruvoipati R, Pilcher D, Buscher H, Botha J, Bailey M. Effects of hypercapnia and hypercapnic acidosis on hospital mortality in mechanically ventilated patients. Crit Care Med. 2017;45:e649–56.CrossRefPubMed
7.
Gendreau S, Geri G, Pham T, Vieillard-Baron A, Mekontso-Dessap A. The role of acute hypercapnia on mortality and short-term physiology in patients mechanically ventilated for ARDS: a systematic review and meta-analysis. Intensive Care Med. 2022;9:1–18.
8.
Tiruvoipati R, Pilcher D, Botha J, Buscher H, Simister R, Bailey M. Association of hypercapnia and hypercapnic acidosis with clinical outcomes in mechanically ventilated patients with cerebral injury. JAMA Neurol. 2018;75:818–26.CrossRefPubMedPubMedCentral
9.
Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy ( approximately 3 ml/kg) combined with extracorporeal CO2 removal versus “conventional” protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med. 2013;39:847–56.CrossRefPubMedPubMedCentral
10.
Braune S, Sieweke A, Brettner F, et al. The feasibility and safety of extracorporeal carbon dioxide removal to avoid intubation in patients with COPD unresponsive to noninvasive ventilation for acute hypercapnic respiratory failure (ECLAIR study): multicentre case-control study. Intensive Care Med. 2016;42:1437–44.CrossRefPubMed
11.
Brunston RL Jr, Zwischenberger JB, Tao W, Cardenas VJ Jr, Traber DL, Bidani A. Total arteriovenous CO2 removal: simplifying extracorporeal support for respiratory failure. Ann Thorac Surg. 1997;64:1599–604.CrossRefPubMed
12.
Combes A, Fanelli V, Pham T, Ranieri VM. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med. 2019;45:592–600.CrossRefPubMed
13.
Tiruvoipati R, Buscher H, Winearls J, et al. Early experience of a new extracorporeal carbon dioxide removal device for acute hypercapnic respiratory failure. Crit Care Resus. 2016;18:261–9.
14.
Terragni PP, Del Sorbo L, Mascia L, et al. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology. 2009;111:826–35.CrossRefPubMed
15.
Staudinger T. Update on extracorporeal carbon dioxide removal: a comprehensive review on principles, indications, efficiency, and complications. Perfusion. 2020;35:492–508.CrossRefPubMed
16.
Tiruvoipati R, Akkanti B, Dinh K, et al. Extracorporeal Carbon Dioxide Removal With the Hemolung in Patients With Acute Respiratory Failure: A Multicenter Retrospective Cohort Study. Crit Care Med. 2023;51:892.CrossRefPubMedPubMedCentral
17.
Combes A, Tonetti T, Fanelli V, et al. Efficacy and safety of lower versus higher CO(2) extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study. Thorax. 2019;74:1179–81.CrossRefPubMed
18.
Conrad SA, Zwischenberger JB, Grier LR, Alpard SK, Bidani A. Total extracorporeal arteriovenous carbon dioxide removal in acute respiratory failure: a phase I clinical study. Intensive Care Med. 2001;27:1340–51.CrossRefPubMed
19.
Augy JL, Aissaoui N, Richard C, et al. A 2-year multicenter, observational, prospective, cohort study on extracorporeal CO(2) removal in a large metropolis area. J Intensive Care. 2019;7:45.CrossRefPubMedPubMedCentral
20.
Giraud R, Banfi C, Assouline B, De Charrière A, Bendjelid K. Very low blood flow carbon dioxide removal system is not effective in a chronic obstructive pulmonary disease exacerbation setting. Artif Organs. 2021;45:479–87.CrossRefPubMed
21.
McNamee JJ, Gillies MA, Barrett NA, et al. Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial. JAMA 2021.
22.
23.
Godet T, Combes A, Zogheib E, et al. Novel CO2 removal device driven by a renal-replacement system without hemofilter A first step experimental validation. Anaesthesia. 2015;34:135–40.
24.
25.
Karagiannidis C, Strassmann S, Brodie D, et al. Impact of membrane lung surface area and blood flow on extracorporeal CO(2) removal during severe respiratory acidosis. Intensive Care Med Exp. 2017;5:34.CrossRefPubMedPubMedCentral
26.
Combes A, Peek GJ, Hajage D, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Med. 2020;46:2048–57.CrossRefPubMedPubMedCentral
27.
Consales G, Zamidei L, Turani F, et al. Combined Renal-Pulmonary Extracorporeal Support with Low Blood Flow Techniques: A Retrospective Observational Study (CICERO Study). Blood Purif. 2022;51:299–308.CrossRefPubMed
28.
Winiszewski H, Aptel F, Belon F, et al. Daily use of extracorporeal CO(2) removal in a critical care unit: indications and results. J Intensive Care. 2018;6:36.CrossRefPubMedPubMedCentral
Metadata
Title
Evaluation of the safety and efficacy of extracorporeal carbon dioxide removal in the critically ill using the PrismaLung+ device
Authors
Ravindranath Tiruvoipati
Jarryd Ludski
Sachin Gupta
Ashwin Subramaniam
Mallikarjuna Ponnapa Reddy
Eldho Paul
Kavi Haji
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01269-2

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Low HDL-C can be a biomarker to predict persistent severe AKI in septic patients? A retrospective cohort study

Research

Local YB-1, Epo, and EpoR concentrations in fractured bones: results from a porcine model of multiple trauma

Review

Effects of low-level laser therapy on orthodontic miniscrew stability: a systematic review

Research

Resveratrol alleviates DSS-induced IBD in mice by regulating the intestinal microbiota-macrophage-arginine metabolism axis

Research

Predicting mammographic density with linear ultrasound transducers

Research

Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study